Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.53 (
sialidase
)
2,694
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Episialin
, which is found on the apical membrane of human endometrial epithelium, has been postulated to act as an antiadhesive factor through the steric hindrance generated by its extensively glycosylated structure. The present studies were designed to test this hypothesis in an in vitro model of endometrial-blastocyst attachment.
Episialin
was expressed in human endometrial carcinoma cells (HEC-1A > RL95-2), and attachment of JAr choriocarcinoma cells to the endometrial cell monolayers was inversely related to
episialin
expression. Treatment of endometrial monolayers with type III
sialidase
increased JAr binding, and this increase was suppressed by HMFG1, a monoclonal antibody specific for
episialin
. The effects of
sialidase
appear to have resulted from a contaminant protease rather than from a loss of sialic acid residues, because
sialidase
preparations other than type III were ineffective. After
sialidase
treatment, conditioned medium from cells treated with type III
sialidase
contained more
episialin
than medium from cells treated with other
sialidase
preparations. Similar attachment-assay results were obtained using O-sialoglycoprotein endopeptidase; after treatment, the increase in JAr binding (>50%) was suppressed by the antiepisialin antibody. These results demonstrate for the first time that
episialin
acts as an antiadhesive agent in a model of human endometrial-blastocyst attachment.
...
PMID:Episialin acts as an antiadhesive factor in an in vitro model of human endometrial-blastocyst attachment. 1085 71
Airway epithelia express sialylated receptors that recognize exogenous danger signals. Regulation of receptor responsiveness to these signals remains incompletely defined. Here, we explore the mechanisms through which the human
sialidase
, neuraminidase-1 (NEU1), promotes the interaction between the sialoprotein,
mucin 1
(
MUC1
), and the opportunistic pathogen, Pseudomonas aeruginosa. P. aeruginosa flagellin engaged the
MUC1
ectodomain (ED), increasing NEU1 association with
MUC1
. The flagellin stimulus increased the association of
MUC1
-ED with both NEU1 and its chaperone/transport protein, protective protein/cathepsin A. Scatchard analysis demonstrated NEU1-dependent increased binding affinity of flagellin to
MUC1
-expressing epithelia. NEU1-driven
MUC1
-ED desialylation rapidly increased P. aeruginosa adhesion to and invasion of the airway epithelium.
MUC1
-ED desialylation also increased its shedding, and the shed
MUC1
-ED competitively blocked P. aeruginosa adhesion to cell-associated
MUC1
-ED. Levels of desialylated
MUC1
-ED were elevated in the bronchoalveolar lavage fluid of mechanically ventilated patients with P. aeruginosa airway colonization. Preincubation of P. aeruginosa with these same ex vivo fluids competitively inhibited bacterial adhesion to airway epithelia, and
MUC1
-ED immunodepletion completely abrogated their inhibitory activity. These data indicate that a prokaryote, P. aeruginosa, in a ligand-specific manner, mobilizes eukaryotic NEU1 to enhance bacterial pathogenicity, but the host retaliates by releasing
MUC1
-ED into the airway lumen as a hyperadhesive decoy receptor.
...
PMID:NEU1 Sialidase Regulates Membrane-tethered Mucin (MUC1) Ectodomain Adhesiveness for Pseudomonas aeruginosa and Decoy Receptor Release. 2596 44
Pseudomonas aeruginosa
(Pa) expresses an adhesin, flagellin, that engages the
mucin 1
(
MUC1
) ectodomain (ED) expressed on airway epithelia, increasing association of
MUC1
-ED with neuraminidase 1 (NEU1) and
MUC1
-ED desialylation. The
MUC1
-ED desialylation unmasks both cryptic binding sites for Pa and a protease recognition site, permitting its proteolytic release as a hyperadhesive decoy receptor for Pa. We found here that intranasal administration of Pa strain K (PAK) to BALB/c mice increases
MUC1
-ED shedding into the bronchoalveolar compartment.
MUC1
-ED levels increased as early as 12 h, peaked at 24-48 h with a 7.8-fold increase, and decreased by 72 h. The a-type flagellin-expressing PAK strain and the b-type flagellin-expressing PAO1 strain stimulated comparable levels of
MUC1
-ED shedding. A flagellin-deficient PAK mutant provoked dramatically reduced
MUC1
-ED shedding compared with the WT strain, and purified flagellin recapitulated the WT effect. In lung tissues, Pa increased association of NEU1 and protective protein/cathepsin A with
MUC1
-ED in reciprocal co-immunoprecipitation assays and stimulated
MUC1
-ED desialylation. NEU1-selective
sialidase
inhibition protected against Pa-induced
MUC1
-ED desialylation and shedding. In Pa-challenged mice,
MUC1
-ED-enriched bronchoalveolar lavage fluid (BALF) inhibited flagellin binding and Pa adhesion to human airway epithelia by up to 44% and flagellin-driven motility by >30%. Finally, Pa co-administration with recombinant human
MUC1
-ED dramatically diminished lung and BALF bacterial burden, proinflammatory cytokine levels, and pulmonary leukostasis and increased 5-day survival from 0% to 75%. We conclude that Pa flagellin provokes NEU1-mediated airway shedding of
MUC1
-ED, which functions as a decoy receptor protecting against lethal Pa lung infection.
...
PMID:Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against
Pseudomonas aeruginosa
lung infection. 3042 16